Description
The HOYA Vivinex™ Toric IOL XY1AT3 is an advanced intraocular lens designed to enhance visual outcomes for patients undergoing cataract surgery with astigmatism. Crafted from hydrophobic acrylic material, this lens offers exceptional optical clarity by being glistening-free and includes UV and blue light filtering properties for added eye protection.
Optic Design
- Aspheric Anterior Surface: Enhances image quality by partially compensating for corneal spherical aberration.
- Toric Posterior Surface: Specifically tailored for astigmatism correction.
- Square-Edged Biconvex Shape: Features a textured edge to reduce posterior capsule opacification (PCO).
Dimensions
- Optic Diameter: 6.00 mm
- Overall Length: 13.00 mm
Power Specifications
- Spherical Power Range: +10.00 D to +30.00 D in 0.50 D increments.
- Cylinder Power Range: 1.00 D to 6.00 D at the IOL plane, with precise increments for tailored correction.
Haptic Design
The lens includes a textured-rough surface with polished sides, engineered for enhanced stability and reduced postoperative rotation. Clinical studies demonstrate over 96% of these lenses rotate ≤5°, ensuring consistent visual performance.
Injector System
Preloaded in the multiSert™ injector system, the lens allows for a recommended incision size of 2.20 mm, facilitating a minimally invasive procedure. The injector tip has an outer diameter of 1.70 mm, promoting precise and safe implantation.
Advanced Features
- Active Oxygen Processing: Utilizes UV-ozone treatment for high surface precision and biocompatibility.
- Proprietary Aspheric Optic Design: Aims to improve image quality and reduce PCO incidence.
Intended Use
This lens is intended for implantation in the posterior chamber of the eye and is designed for use by healthcare professionals. It is a crucial tool for achieving optimal visual outcomes in patients with cataract and astigmatism.
Additional Information
In Japan, only tinted lenses are available. Cylinder power calculations can be performed using the HOYA Toric Calculator with the Abulafia-Koch Regression formula. For comprehensive indications and contraindications, healthcare providers should refer to the official product documentation.